Search results for "Radiation"

showing 10 items of 5298 documents

The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision

2017

Curative treatment of rectal cancer depends on an optimal surgical resection, with the addition of neoadjuvant radiotherapy (RT) with or without concomitant chemotherapy (ChT) in more advanced tumors. The role of adjuvant ChT is controversial and a more intensified neoadjuvant approach with the addition of ChT before or after RT, or even as single modality, is currently being explored in trials. A systematic review selecting randomised phase II and III trials on the role of ChT in localized rectal cancer was performed. Data show that neoadjuvant ChRT improves locoregional control in resected rectal cancer. Short-course RT (SCRT) could give similar outcomes to ChRT. The addition of oxaliplat…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAntineoplastic Agents03 medical and health sciences0302 clinical medicineClinical Trials Phase II as TopicPreoperative chemoradiationInternal medicineMedicineCombined Modality TherapyHumansRadiology Nuclear Medicine and imagingRectal cancerNeoadjuvant therapyRandomized Controlled Trials as TopicChemotherapybusiness.industryRectal NeoplasmsGeneral MedicineAdjuvant chemotherapy; Preoperative chemoradiation; Rectal cancermedicine.diseaseCombined Modality TherapyNeoadjuvant TherapyOxaliplatinAdjuvant chemotherapyRadiation therapy030104 developmental biologyOncologyClinical Trials Phase III as Topic030220 oncology & carcinogenesisConcomitantRadiotherapy AdjuvantbusinessAdjuvantmedicine.drug
researchProduct

Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned ci…

2017

// Pierpaolo Pastina 1 , Valerio Nardone 1 , Cirino Botta 2 , Stefania Croci 1 , Paolo Tini 1 , Giuseppe Battaglia 1 , Veronica Ricci 3 , Maria Grazia Cusi 4 , Claudia Gandolfo 4 , Gabriella Misso 5 , Silvia Zappavigna 5 , Michele Caraglia 5,6 , Antonio Giordano 6,7 , Donatella Aldinucci 8 , Pierfrancesco Tassone 2,6 , Pierosandro Tagliaferri 2 , Luigi Pirtoli 1 and Pierpaolo Correale 1,9 1 Radiotherapy Unit, Department of Medicine, Surgery, and Neuroscience, Siena University Hospital, Siena, Italy 2 Medical Oncology Unit, AUO “Mater Domini”, “Magna Graecia” University, Catanzaro, Italy 3 Radiology Unit,Department of Medicine, Surgery, and Neuroscience, Siena University Hospital, Siena, Ita…

0301 basic medicineOncologymedicine.medical_specialtyRetrospective analysiBevacizumabmedicine.medical_treatmentRetrospective analysisNSCLC03 medical and health sciences0302 clinical medicineInternal medicineMedicineLung cancerEtoposideCisplatinbusiness.industryMetronomic chemotherapyAbscopal effectmedicine.diseaseMetronomic ChemotherapyImmune-modulationSurgeryRadiation therapyRadiation therapyRegimen030104 developmental biologyOncology030220 oncology & carcinogenesisNSCLC; immune-modulation; metronomic chemotherapy; radiation therapy; retrospective analysisbusinessmedicine.drugResearch Paper
researchProduct

Identification of responders to immune checkpoint therapy: which biomarkers have the highest value?

2019

Evasion of immune recognition by the innate and acquired immune system is a major principle of tumour cells and belongs to the hallmarks of cancer. Immune checkpoint inhibitor-based cancer therapies targeting the co-inhibitory receptors CTLA-4 or PD-1 have received enormous scientific and clinical attention during the last few years, because of promising clinical results observed in the treatment of different cancer entities including melanoma and cutaneous squamous cell carcinoma. However, the enthusiasm about the effects of the immune checkpoint inhibitors is muted as only a subfraction of patients shows a stable clinical response. To predefine the patient cohorts that may benefit from im…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentDermatology03 medical and health sciences0302 clinical medicineNeoplasmsInternal medicineBiomarkers TumormedicineHumansChemotherapybusiness.industryMelanomaCancerAcquired immune systemmedicine.diseaseImmune checkpointRadiation therapyTreatment Outcome030104 developmental biologyInfectious DiseasesThe Hallmarks of Cancer030220 oncology & carcinogenesisBiomarker (medicine)ImmunotherapybusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

Differential Superiority of Heavy Charged-Particle Irradiation to X-Rays: Studies on Biological Effectiveness and Side Effect Mechanisms in Multicell…

2016

This review is focused on the radiobiology of carbon ions compared to X-rays using multicellular models of tumors and normal mucosa. The first part summarizes basic radiobiological effects, as observed in cancer cells. The second, more clinically oriented part of the review, deals with radiation-induced cell migration and mucositis. Multicellular spheroids from V79 hamster cells were irradiated with X-rays or carbon ions under ambient or restricted oxygen supply conditions. Reliable oxygen enhancement ratios could be derived to be 2.9, 2.8, and 1.4 for irradiation with photons, (12)C(+6) in the plateau region, and (12)C(+6) in the Bragg peak, respectively. Similarly, a relative biological e…

0301 basic medicinePathologymedicine.medical_specialtyCancer Researchcell migrationMotilityReviewBiologylcsh:RC254-28203 medical and health sciences0302 clinical medicinerelative biological effectivenessRadioresistancemedicineRelative biological effectivenessorganotypic tumor and mucosa culturesparticle irradiationCell migrationOxygen enhancement ratio (OER)lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensrelative biological effectiveness (RBE)030104 developmental biologymucositisOncologyradiobiologyCell cultureApoptosis030220 oncology & carcinogenesisCancer cellOxygen enhancement ratioBiophysicsoxygen enhancement ratioFrontiers in Oncology
researchProduct

High-Intensity Focused Ultrasound- and Radiation Therapy-Induced Immuno-modulation: Comparison and Potential Opportunities

2017

In recent years, high-intensity focused ultrasound (HIFU) has emerged as a new and promising non-invasive and non-ionizing ablative technique for the treatment of localized solid tumors. Extensive pre-clinical and clinical studies have evidenced that, in addition to direct destruction of the primary tumor, HIFU-thermoablation may elicit long-term systemic host anti-tumor immunity. In particular, an important consequence of HIFU treatment includes the release of tumor-associated antigens (TAAs), the secretion of immuno-suppressing factors by cancer cells and the induction of cytotoxic T lymphocyte (CTL) activity. Radiation therapy (RT) is the main treatment modality used for many types of tu…

0301 basic medicinePathologymedicine.medical_specialtyRadiology Nuclear Medicine and ImagingAcoustics and Ultrasonicsmedicine.medical_treatmentBiophysicsImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemNeoplasmsmedicineBystander effectHumansCancerChemotherapyRadiological and Ultrasound Technologybusiness.industryCancermedicine.diseasePrimary tumorThermal ablationHigh-intensity focused ultrasoundRadiation therapyImmuno-therapyRadiation therapyTumor vaccine030104 developmental biologyBiophysicHigh-intensity focused ultrasound030220 oncology & carcinogenesisCancer cellCancer researchHigh-Intensity Focused Ultrasound AblationAnti-tumor immunitybusinessAnti-tumor immunity; Cancer; High-intensity focused ultrasound; Immuno-therapy; Radiation therapy; Thermal ablation; Tumor vaccine
researchProduct

Parametrical Optomechanical Oscillations in PhoXonic Whispering Gallery Mode Resonators

2019

AbstractWe report on the experimental and theoretical analysis of parametrical optomechanical oscillations in hollow spherical phoxonic whispering gallery mode resonators due to radiation pressure. The optically excited acoustic eigenmodes of the phoxonic cavity oscillate regeneratively leading to parametric oscillation instabilities.

0301 basic medicinePhysics::Opticslcsh:MedicineArticlemicrobubbles03 medical and health sciencesResonatorwhispering gallery mode resonators0302 clinical medicineOpticswhispering gallery modeslcsh:SciencePhysicsMultidisciplinarymicrobubble resonatorsbusiness.industryParametric oscillationlcsh:RUNESCO::FÍSICA::Óptica ::Fibras ópticasstimulated brillouin scatteringkerr modulation030104 developmental biologyRadiation pressureOptics and photonics:FÍSICA::Óptica ::Fibras ópticas [UNESCO]Excited stateOther photonicsparametrical optomechanical oscillationslcsh:QWhispering-gallery wavebusiness030217 neurology & neurosurgeryScientific Reports
researchProduct

Modulating tumor hypoxia by nanomedicine for effective cancer therapy

2016

Hypoxia, a characteristic feature of tumors, is indispensable to tumor angiogenesis, metastasis, and multi drug resistance. Hypoxic avascular regions, deeply embedded inside the tumors significantly hinder delivery of therapeutic agents. The low oxygen tension results in resistance to the current applied anti-cancer therapeutics including radiotherapy, chemotherapy, and photodynamic therapy, the efficacy of which is firmly tied to the level of tumor oxygen supply. However, emerging data indicate that nanocarriers/nanodrugs can offer substantial benefits to improve the efficacy of current therapeutics, through modulation of tumor hypoxia. This review aims to introduce the most recent advance…

0301 basic medicinePhysiologymedicine.medical_treatmentClinical BiochemistryPhotodynamic therapy02 engineering and technologyPharmacologyBiologyMetastasis03 medical and health sciencesNeoplasmsmedicineHumansDrug CarriersNeovascularization PathologicTumor hypoxiaCell BiologyTumor OxygenationHypoxia (medical)021001 nanoscience & nanotechnologymedicine.diseaseCell HypoxiaNanostructuresOxygenRadiation therapyNanomedicine030104 developmental biologyTumor HypoxiaNanomedicinemedicine.symptomNanocarriers0210 nano-technologyJournal of Cellular Physiology
researchProduct

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized…

2019

Objectives: Concomitant chemo-radiation is the standard treatment for unresectable stage III non-small cell lung cancer (LA-NSCLC), The aim of this study was to assess the safety and efficacy of oral vinorelbine and cisplatin (OVP) compared with etoposide and cisplatin (EP), both in combination with radiotherapy, in this setting. Material and methods: An open-label, randomized phase II trial was undertaken including 23 hospitals in Spain. Adults with untreated unresectable stage III NSCLC were randomizedl:1 to receive: oral vinorelbine (days 1 and 8 with cisplatin on day 1 in 3-week cycles; 2 cycles of induction, 2 cycles in concomitance) or etoposide (days 1-5 and 29-32 with cisplatin on d…

0301 basic medicinePulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDisease-free survivalmedicine.medical_treatmentNeoplasm metastasisAdministration OralVinorelbine03 medical and health sciences0302 clinical medicineNon-small cell lung cancerInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalneoplasmsEtoposideAgedNeoplasm StagingEtoposideCisplatinbusiness.industryStandard treatmentVinorelbineChemoradiotherapyMiddle AgedPhase IIrespiratory tract diseasesRadiation therapySurvival RateClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisConcomitantFemalePatient SafetyCisplatinbusinessClinical trial Disease-free survival Etoposide Neoplasm metastasis Non-small cell lung cancer Phase II Vinorelbinemedicine.drug
researchProduct

Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.

2019

Approximately one third of patients with non-small-cell lung cancer (NSCLC) present with stage III or locally advanced NSCLC. These patients have historically been managed with chemoradiotherapy. However, outcomes for these patients remain poor, with a 5-year survival rate between 15% and 32%. Immune checkpoint inhibitors have revolutionized the treatment of patients with NSCLC. One such agent, durvalumab, a selective high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 binding to programmed cell death protein 1 and cluster of differentiation 80, was recently approved in the consolidation setting after completion of definitive platinum-based c…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyDurvalumabLung Neoplasmsmedicine.medical_treatmentContext (language use)03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansLung cancerSurvival rateImmune Checkpoint InhibitorsPneumonitisbusiness.industryChemoradiotherapyPneumoniamedicine.diseasePrognosisImmune checkpointRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessChemoradiotherapyClinical lung cancer
researchProduct

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

2016

Exclusive chemoradiotherapy (CRT) delivering 50 Gy over 5 weeks with cisplatin and fluorouracil-based chemotherapy is a cornerstone in locally advanced esophageal cancer or non-operable patients since the results of the pivotal study of US Intergroup RTOG-8501 (1). This trial has successfully demonstrated that some patients with esophageal carcinoma may be long-term survivors so that this treatment is now definitely accepted as curative (2). Nevertheless the prognosis is still very disappointing with a 5-year overall survival rate of approximately 25%. Attempts to improve overall survival by escalating the dose of radiotherapy with concurrent cisplatin and fluorouracil has been assessed in …

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtymedicine.medical_treatmentLocally advancedCetuximab[SDV.CAN]Life Sciences [q-bio]/CancerOutcomes[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[ SDV.CAN ] Life Sciences [q-bio]/CancerIntensity-Modulated Radiotherapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineComputingMilieux_MISCELLANEOUSCapecitabineCisplatinChemotherapybusiness.industryCarcinomaInduction ChemotherapyEsophageal cancermedicine.diseaseRadiation-Therapy3. Good healthRadiation therapyEditorial030104 developmental biologyChemoradiationFluorouracil030220 oncology & carcinogenesisIi Randomized-TrialCisplatinbusiness[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractChemoradiotherapymedicine.drug
researchProduct